Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers.
Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers.
复制标题
DOI：
10.2147/ijn.s24326
复制
发表时间：
2012
影响因子：
8
通讯作者：
Davaran S
中科院分区：
文献类型：
--
作者：
Akbarzadeh A;Mikaeili H;Zarghami N;Mohammad R;Barkhordari A;Davaran S
超顺磁性氧化铁纳米颗粒是一种具有吸引力的材料，已广泛用于药物递送、诊断成像和治疗应用的医学中。在我们的研究中，超顺磁性氧化铁纳米粒子和抗癌药物盐酸阿霉素，封装到聚（D，L-乳酸-羟基乙酸）聚（乙二醇）（PLGA-PEG）纳米粒子的局部治疗。由超顺磁性氧化铁纳米颗粒赋予的磁性可以帮助将纳米颗粒保持在具有外部磁体的关节中。以不同分子量的聚乙二醇（PEG 2000、PEG 3000和PEG 4000）为引发剂，通过D，L-丙交酯和乙交酯的开环聚合，合成了一系列PLGA：PEG三嵌段共聚物。这些共聚物的本体性质，其特征在于使用1H核磁共振光谱，凝胶渗透色谱，傅立叶变换红外光谱，和差示扫描量热法。此外，所得颗粒的特征在于通过X-射线粉末衍射，扫描电子显微镜，和振动样品磁强计。PLGA：PEG 2000和PLGA：PEG 3000三嵌段共聚物的阿霉素包封量降低，但PLGA：PEG 4000三嵌段共聚物的阿霉素包封量在很大程度上增加。这是由于共混的三嵌段共聚物的吸水能力增加，其将更多的阿霉素分子封装到溶胀的共聚物基质中。PLGA：PEG 2000、PLGA：PEG 3000和PLGA：PEG 4000共聚物修饰的Fe 3 O 4磁性纳米粒的药物包封率分别为69.5%、73%和78%，且释放动力学可控。体外细胞毒性试验表明，Fe 3 O 4-PLGA：PEG 4000磁性纳米粒无细胞毒性，具有良好的生物相容性。这些纳米粒子具有生物医学应用的潜力。未来的工作包括在体内研究这些纳米粒子在肺癌治疗中的靶向能力和有效性。
Superparamagnetic iron oxide nanoparticles are attractive materials that have been widely used in medicine for drug delivery, diagnostic imaging, and therapeutic applications. In our study, superparamagnetic iron oxide nanoparticles and the anticancer drug, doxorubicin hydrochloride, were encapsulated into poly (D, L-lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment. The magnetic properties conferred by superparamagnetic iron oxide nanoparticles could help to maintain the nanoparticles in the joint with an external magnet. A series of PLGA:PEG triblock copolymers were synthesized by ring-opening polymerization of D, L-lactide and glycolide with different molecular weights of polyethylene glycol (PEG2000, PEG3000, and PEG4000) as an initiator. The bulk properties of these copolymers were characterized using 1H nuclear magnetic resonance spectroscopy, gel permeation chromatography, Fourier transform infrared spectroscopy, and differential scanning calorimetry. In addition, the resulting particles were characterized by x-ray powder diffraction, scanning electron microscopy, and vibrating sample magnetometry. The doxorubicin encapsulation amount was reduced for PLGA:PEG2000 and PLGA:PEG3000 triblock copolymers, but increased to a great extent for PLGA:PEG4000 triblock copolymer. This is due to the increased water uptake capacity of the blended triblock copolymer, which encapsulated more doxorubicin molecules into a swollen copolymer matrix. The drug encapsulation efficiency achieved for Fe3O4 magnetic nanoparticles modified with PLGA:PEG2000, PLGA:PEG3000, and PLGA:PEG4000 copolymers was 69.5%, 73%, and 78%, respectively, and the release kinetics were controlled. The in vitro cytotoxicity test showed that the Fe3O4-PLGA:PEG4000 magnetic nanoparticles had no cytotoxicity and were biocompatible. There is potential for use of these nanoparticles for biomedical application. Future work includes in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of lung cancer.